RonacMamtaniMDMSCE

PubMed

• Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
  Konstantinos Tsingas, Ravi B Parikh, Dina Elsouda, Lisa Mucha, Rupali Fuldeore, Rebecca A Hubbard, Ronac Mamtani> ;Urologic Oncology. 2024 Jun 1
• Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer per...
  Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer> ;Journal of Medical Economics. 2024 Apr 4
• Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
  Rosenberg, J., Mamtani, R., Sonpavde, G., Loriot, Y., Duran, I., Lee, J., Matsubara, N., Vulsteke, C., Castellano, D., Sridhar, S., Pappot, H., Gurney, H., Bedke, J., ...> ;European Urology. 2024 Feb 27
• Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
  Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G Chan, Sara Lewis, Bassam El Achkar, Tanya B Dorff, Jeremy Paul Cetnar, Brock O Nei...> ;Nature Medicine. 2024 Apr 1
• The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer.
  Erin M Bange, Yimei Li, Pallavi Kumar, Abigail Doucette, Peter Gabriel, Ravi Parikh, Eric H Li, Ronac Mamtani, Kelly D Getz> ;Cancer. 2024 Feb 15
• 11 citations
  Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
  Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2023 Nov 1
• Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival.
  Ben Boursi, E Paul Wileyto, Ronac Mamtani, Susan M Domchek, Talia Golan, Ryan Hood, Kim A Reiss> ;JAMA Network Open. 2023 Nov 1
• Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens.
  William P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, Aditi Singh, Christine Ciunci, Christopher D'Avella, Charu Aggarwal, Roger B Cohen, Corey J Langer, Ronac Mamtani, Me...> ;Clinical Lung Cancer. 2023 Sep 1
• 15 citations
  Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
  Lova Sun, Benjamin Bleiberg, Wei-Ting Hwang, Melina E Marmarelis, Corey J Langer, Aditi Singh, Roger B Cohen, Ronac Mamtani, Charu Aggarwal> ;JAMA Oncology. 2023 Aug 1
• Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation.
  Daniel T Vader, Ronac Mamtani, Yun Li, Sandra D Griffith, Gregory S Calip, Rebecca A Hubbard> ;Epidemiology. 2023 Jul 1
• 2 citations
  Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer.
  Ronac Mamtani, Hanxi Zhang, Ravi B Parikh, Khilna Patel, Haojie Li, Kentaro Imai, Rebecca A Hubbard> ;JAMA Network Open. 2023 Apr 3
• 2 citations
  Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.
  Timothy J Brown, Ronac Mamtani, Phyllis A Gimotty, Thomas B Karasic, Yu-Xiao Yang> ;Journal of Cancer Research and Clinical Oncology. 2023 Jun 1
• Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study.
  Jeromy W Gotschall, C Kendall Major, Linda A Jacobs, Abigail Blauch, Donna Pucci, Steven C Palmer, Ronac Mamtani> ;BJUI Compass. 2023 Mar 1
• 1 citations
  Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.
  Mohsin Shah, Ronac Mamtani, Melina E Marmarelis, Sean Hennessy> ;Clinical Lung Cancer. 2023 May 1
• 7 citations
  Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.
  Ravi B Parikh, Rebecca A Hubbard, Erkuan Wang, Trevor J Royce, Aaron B Cohen, Amy S Clark, Ronac Mamtani> ;JAMA Oncology. 2023 Apr 1
• 15 citations
  Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.
  Teja Voruganti, Pamela R Soulos, Ronac Mamtani, Carolyn J Presley, Cary P Gross> ;JAMA Oncology. 2023 Mar 1
• Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma.
  Haojie Li, Mehmet Burcu, Srinivas Annavarapu, Karen Wells, Kentaro Imai, Blanca Homet Moreno, Puneet Singhal, Ronac Mamtani, Doshi, G.> ;Frontiers in Oncology. 2023 Jan 1
• Comparison of the 'iROC' trial participants to patients with bladder cancer in the United States undergoing radical cystectomy.
  Daniel S Roberson, Leilei Xia, Daniel J Lee, Phillip M Pierorazio, S Bruce Malkowicz, Ronac Mamtani, Thomas J Guzzo, Trinity J Bivalacqua> ;BJU International. 2023 Apr 1
• 4 citations
  Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden.
  Christopher D Herrera, Carmen E Guerra, Vivek Narayan, Thomas J Guzzo, Ronac Mamtani, Daniel J Lee, Gregory E Tasian, Ruchika Talwar> ;Urologic Oncology. 2023 Feb 1
• 87 citations
  NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
  Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Rich...> ;Journal of the National Comprehensive Cancer Network. 2022 Aug 1
• 1 citations
  Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors.
  Erin M Bange, Kerry Coughlin, Wenrui Li, Elizabeth Moriarty, Timothy J Brown, Lawrence N Shulman, Ronac Mamtani> ;JAMA Network Open. 2022 Aug 1
• 4 citations
  Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Ca...
  Mohsin Shah, Melina E Marmarelis, Ronac Mamtani, Sean Hennessy> ;Clinical Lung Cancer. 2022 Dec 1
• Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality.
  Daniel T Vader, Ravi B Parikh, Haojie Li, Kentaro Imai, Rebecca A Hubbard, Ronac Mamtani> ;JNCI Cancer Spectrum. 2022 Jul 1
• Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma.
  Ofer Margalit, Shun Yu, Einat Shacham-Shmueli, Gal Strauss, Yu-Xiao Yang, Yaacov R Lawrence, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Rona...> ;Journal of Cancer Research and Clinical Oncology. 2022 Jul 1
• Correction to: Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma.
  Ofer Margalit, Shun Yu, Einat Shacham-Shmueli, Gal Strauss, Yu-Xiao Yang, Yaacov R Lawrence, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Rona...> ;Journal of Cancer Research and Clinical Oncology. 2022 Jul 1
• Join now to see all

Journal Articles

• Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs Data  
  Ravi Vinnakota, Keith Sigel, Joshua M Bauml, Roger B Cohen, Nevena Damjanov, Corey J Langer, Ronac Mamtani, Charu Aggarwal, Christina Knepley, Juan Wisnivesky, Cancer